Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: NetraMark Holdings Inc.

Market Cap 74.2M 52.89M 45.63M 41.95M 39.49M 4.99B 74.82M 497M 194M 2.45B 199M 194M 8.48B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 74.2M 52.89M 45.63M 41.95M 39.49M 4.99B 74.82M 497M 194M 2.45B 199M 194M 8.48B EV / Sales 2026 *
185x
EV / Sales 2027 * -
Free-Float
89.03%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer - 17/02/2022
President - 04/07/2022
Director of Finance/CFO 57 18/07/2022
Director TitleAgeSince
Chairman 40 09/06/2025
Director/Board Member - -
Director/Board Member - 16/06/2022
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-3.77% - - 52.89M
-0.25%-3.26%-21.37%+11.71% 2,815B
-2.59%-3.07%-9.22%+704.69% 313B
+1.00%+7.23%+243.07%+782.57% 123B
+0.55%+2.10%+31.99%+68.49% 107B
+0.29%+0.60%-3.09%+5.40% 88.41B
-2.71%-6.72%+68.03%+126.00% 80.67B
-0.32%+6.58%-41.34%+49.21% 55.64B
+4.29%+11.71%-0.66%+70.41% 42.34B
+7.13%+19.65%-49.31%+24.58% 34.38B
Average +0.93%+4.35%+24.23%+204.78% 406.61B
Weighted average by Cap. -0.22%-2.84%-7.81%+102.26%

Financials

2026 *2027 *
Net sales 401K 286K 247K 227K 213K 26.97M 404K 2.69M 1.05M 13.24M 1.07M 1.05M 45.79M -
Net income - -
Net Debt - -
Logo NetraMark Holdings Inc.
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.
Employees
-

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!